<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Public Datasets | AMRcloud</title>
    <link>https://amrcloud.net/en/project/</link>
      <atom:link href="https://amrcloud.net/en/project/index.xml" rel="self" type="application/rss+xml" />
    <description>Public Datasets</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>AMRcloud © 2021</copyright>
    <image>
      <url>https://amrcloud.net/img/amr-cloud-logo-text.png</url>
      <title>Public Datasets</title>
      <link>https://amrcloud.net/en/project/</link>
    </image>
    
    <item>
      <title>CAZ-AVI Disk Study</title>
      <link>https://amrcloud.net/en/project/cazavi-1-2/</link>
      <pubDate>Tue, 09 Feb 2021 15:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/cazavi-1-2/</guid>
      <description>&lt;h3 id=&#34;study-objective&#34;&gt;Study Objective:&lt;/h3&gt;
&lt;p&gt;To assess the &lt;em&gt;in vitro&lt;/em&gt; activity of ceftazidime-avibactam combination against clinical Enterobacterales and &lt;em&gt;Pseudomonas aeruginosa&lt;/em&gt; isolates in various regions of Russia based on results of local susceptibility testing by disk diffusion method&lt;/p&gt;
&lt;h3 id=&#34;dataset&#34;&gt;Dataset:&lt;/h3&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th&gt;&lt;/th&gt;
&lt;th&gt;&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td&gt;&lt;strong&gt;Bacterial isolates:&lt;/strong&gt;&lt;/td&gt;
&lt;td&gt;22 121&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;  Enterobacterales:&lt;/td&gt;
&lt;td&gt;17 456&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;  &lt;em&gt;Pseudomonas aeruginosa:&lt;/em&gt;&lt;/td&gt;
&lt;td&gt;4 665&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;strong&gt;Stage I:&lt;/strong&gt;&lt;/td&gt;
&lt;td&gt;November 11, 2018 - April 28, 2019&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;strong&gt;Stage II:&lt;/strong&gt;&lt;/td&gt;
&lt;td&gt;January 01, 2020 - December 28, 2020&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;strong&gt;Participating centers:&lt;/strong&gt;&lt;/td&gt;
&lt;td&gt;160 hospitals in 61 cities of Russian Federation&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;h3 id=&#34;inclusion-criteria&#34;&gt;Inclusion Criteria:&lt;/h3&gt;
&lt;p&gt;Consecutive, non-duplicate (one per patient) clinical isolates of Enterobacterales and &lt;em&gt;P. aeruginosa&lt;/em&gt; isolated from patients with clinical and laboratory signs of infections of different sites (intraabdominal, respiratory, skin and soft tissue, bones and joints, urinary, bloodstream, and CNS).&lt;/p&gt;
&lt;h3 id=&#34;exclusion-criteria&#34;&gt;Exclusion Criteria:&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Isolates other than Enterobacterales and &lt;em&gt;P. aeruginosa&lt;/em&gt;;&lt;/li&gt;
&lt;li&gt;Repeated isolates of the same species isolated from the same patient;&lt;/li&gt;
&lt;li&gt;Colonizing isolates isolated from patients without clinical signs of infection or from the environment for infection control purposes;&lt;/li&gt;
&lt;li&gt;Isolates for which the required information is the electronic CRF is missing or incomplete.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;study-procedures-and-data-collection&#34;&gt;Study Procedures and Data Collection:&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Isolation, species identification, and antimicrobial susceptibility testing of bacterial isolates is performed in the laboratories of the participating centers.&lt;/li&gt;
&lt;li&gt;Information on the source of each isolate and its susceptibility to ceftazidime-avibactam (the diameter of inhibition zone around the disk) is entered into an electronic CRF.&lt;/li&gt;
&lt;li&gt;Data on susceptibilities (zone diameters or MICs) to oxyimino-cephalosporins and/or carbapenems is entered into an electronic CRF, if available.&lt;/li&gt;
&lt;li&gt;Data on the method(s) and result(s) of carbapenemase detection is entered into an electronic CRF, if available.&lt;/li&gt;
&lt;li&gt;Susceptibility categories of isolates are determined automatically according to current 
&lt;a href=&#34;http://www.eucast.org/clinical_breakpoints/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;EUCAST Clinical Breakpoints&lt;/a&gt;.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;study-coordinator&#34;&gt;Study Coordinator&lt;/h3&gt;
&lt;p&gt;Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy 
&lt;a href=&#34;https://www.antibiotic.ru/iacmac/about/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;IACMAC&lt;/a&gt;&lt;/p&gt;
&lt;h3 id=&#34;study-sponsor&#34;&gt;Study Sponsor&lt;/h3&gt;
&lt;p&gt;
&lt;a href=&#34;https://www.pfizer.ru/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Pfizer Inc.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>DARMIS 2009-2011 &amp; 2017-2018</title>
      <link>https://amrcloud.net/en/project/darmis/</link>
      <pubDate>Sun, 14 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/darmis/</guid>
      <description>&lt;h3 id=&#34;organisers&#34;&gt;Organisers&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)&lt;/li&gt;
&lt;li&gt;Russian Society of Urologists&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;annotation&#34;&gt;Annotation&lt;/h3&gt;
&lt;p&gt;This dataset presents the data on antibiotic resistance of community-acquired uropathogens isolated from midstream urine samples of:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;adults with symptomatic UTI (cystitis, pyelonephritis);&lt;/li&gt;
&lt;li&gt;children and adolescents under 18 years with symptomatic UTI (cystitis, pyelonephritis);&lt;/li&gt;
&lt;li&gt;pregnant women with symptomatic UTI (cystitis and pyelonephritis) and asymptomatic bacteriuria.&lt;/li&gt;
&lt;/ul&gt;
&lt;h4 id=&#34;the-study-was-conducted-in-two-periods&#34;&gt;The study was conducted in two periods:&lt;/h4&gt;
&lt;ul&gt;
&lt;li&gt;DARMIS 2009-2011: &lt;strong&gt;28 centers, 20 cities&lt;/strong&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Russia&lt;/strong&gt;: Voronezh, Yekaterinburg, Irkutsk, Kazan, Krasnodar, Moscow, Omsk, Rostov-on-Don, Samara, St. Petersburg, Seversk, Smolensk, Surgut, Tomsk, Tyumen, Ufa, Chelyabinsk, Yakutsk;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Belarus&lt;/strong&gt;: Gomel;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Kazakhstan&lt;/strong&gt;: Karaganda.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;li&gt;DARMIS 2017-2018: &lt;strong&gt;34 centers, 26 cities&lt;/strong&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Russia&lt;/strong&gt;: Bratsk, Voronezh, Yekaterinburg, Irkutsk, Yoshkar-Ola, Kazan, Kirov, Krasnodar, Nizhnevartovsk, Novokuznetsk, Novosibirsk, Omsk, Rostov-on-Don, Samara, St. Petersburg, Seversk, Smolensk, Surgut, Tolyatti, Tomsk, Ulyanovsk, Chelyabinsk, Yakutsk, Yaroslavl;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Belarus&lt;/strong&gt;: Gomel;&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Kazakhstan&lt;/strong&gt;: Karaganda.&lt;/li&gt;
&lt;/ul&gt;
&lt;/li&gt;
&lt;/ul&gt;
&lt;h4 id=&#34;antibiotic-susceptibility-testing&#34;&gt;Antibiotic Susceptibility Testing&lt;/h4&gt;
&lt;p&gt;Minimum inhibitory concentrations (MICs) of antibiotics were determined by reference broth microdilution method (BMD) in Mueller-Hinton broth according to ISO 20776-1:2006 at the Central Laboratory of the Institute of Antimicrobial Chemotherapy (IAC), Smolensk State Medical University (SSMU)&lt;/p&gt;
&lt;h4 id=&#34;interpretation-of-mics&#34;&gt;Interpretation of MICs&lt;/h4&gt;
&lt;p&gt;Clinical susceptibility categories were assigned according to the 
&lt;a href=&#34;http://www.eucast.org/clinical_breakpoints/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC Clinical breakpoints v.11.0, 2021&lt;/a&gt;&lt;/p&gt;
&lt;h3 id=&#34;darmis-2009-2011-study-group&#34;&gt;DARMIS 2009-2011 Study Group&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Agapova E.D. (Irkutsk)&lt;/li&gt;
&lt;li&gt;Ankirskaya A.S. (Moscow)&lt;/li&gt;
&lt;li&gt;Elokhina E.V. (Omsk)&lt;/li&gt;
&lt;li&gt;Galeeva O.P. (Kazan)&lt;/li&gt;
&lt;li&gt;Gudkova L.V. (Tomsk)&lt;/li&gt;
&lt;li&gt;Gumenetskiy D.V. (Chelyabinsk)&lt;/li&gt;
&lt;li&gt;Khasanova S.G. (Ufa)&lt;/li&gt;
&lt;li&gt;Khokhlyavina R.M. (Tyumen)&lt;/li&gt;
&lt;li&gt;Kogan M.I. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Kozlova L.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Lavrinenko A.V. (Karaganda, Kazakhstan)&lt;/li&gt;
&lt;li&gt;Loginov Yu.A. (Smolensk)&lt;/li&gt;
&lt;li&gt;Malev I.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Morozov M.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Moskvitina E.N. (Seversk)&lt;/li&gt;
&lt;li&gt;Multykh I.G. (Krasnodar)&lt;/li&gt;
&lt;li&gt;Naboka Yu.L. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Nastausheva T.L. (Voronezh)&lt;/li&gt;
&lt;li&gt;Nikolskaya I.G. (Moscow)&lt;/li&gt;
&lt;li&gt;Ortenberg E.A. (Tyumen)&lt;/li&gt;
&lt;li&gt;Oskina E.A. (Samara)&lt;/li&gt;
&lt;li&gt;Palagin I.S. (Smolensk)&lt;/li&gt;
&lt;li&gt;Perevalova E.Yu. (Yekaterinburg)&lt;/li&gt;
&lt;li&gt;Polukhina O.V. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Rozanova S.M. (Yekaterinburg)&lt;/li&gt;
&lt;li&gt;Safina A.I. (Kazan)&lt;/li&gt;
&lt;li&gt;Savicheva A.M. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Sekhin S.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Skalskiy S.V. (Omsk)&lt;/li&gt;
&lt;li&gt;Tapalskiy D.V. (Gomel, Belarus)&lt;/li&gt;
&lt;li&gt;Tatarinova O.V. (Yakutsk)&lt;/li&gt;
&lt;li&gt;Trapeznikova B.V. (Surgut)&lt;/li&gt;
&lt;li&gt;Valiullina I.R. (Kazan)&lt;/li&gt;
&lt;li&gt;Zhestkov A.V. (Samara)&lt;/li&gt;
&lt;li&gt;Zulkarneev R.Kh. (Ufa)&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;darmis-2017-2018-study-group&#34;&gt;DARMIS 2017-2018 Study Group&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Amineva P.G. (Yekaterinburg)&lt;/li&gt;
&lt;li&gt;Becker G.G. (Novosibirsk)&lt;/li&gt;
&lt;li&gt;Bulkin A.N. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Bykonya S.A. (Tomsk)&lt;/li&gt;
&lt;li&gt;Chastoedova A.N. (Kirov)&lt;/li&gt;
&lt;li&gt;Domanskaya O.V. (Novokuznetsk)&lt;/li&gt;
&lt;li&gt;Elokhina E.V. (Omsk)&lt;/li&gt;
&lt;li&gt;Ershova M.G. (Yaroslavl)&lt;/li&gt;
&lt;li&gt;Ivanova I.A. (Yoshkar-Ola)&lt;/li&gt;
&lt;li&gt;Khaidarshina N.E. (Chelyabinsk)&lt;/li&gt;
&lt;li&gt;Khusnutdinova T.A. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Kogan M.I. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Kulchavenya E.V. (Novosibirsk)&lt;/li&gt;
&lt;li&gt;Lavrinenko A.V. (Karaganda, Kazakhstan)&lt;/li&gt;
&lt;li&gt;Lyamin A.V. (Samara)&lt;/li&gt;
&lt;li&gt;Malev I.V. (Smolensk)&lt;/li&gt;
&lt;li&gt;Malyavin A.I. (Ulyanovsk)&lt;/li&gt;
&lt;li&gt;Martyanova N.M. (Tolyatti)&lt;/li&gt;
&lt;li&gt;Moskvitina E.N. (Seversk)&lt;/li&gt;
&lt;li&gt;Mutin M.Yu. (Bratsk)&lt;/li&gt;
&lt;li&gt;Naboka Yu.L. (Rostov-on-Don)&lt;/li&gt;
&lt;li&gt;Nikiforovskaya N.N. (Smolensk)&lt;/li&gt;
&lt;li&gt;Palagin I.S. (Smolensk)&lt;/li&gt;
&lt;li&gt;Plugin P.S. (Novosibirsk)&lt;/li&gt;
&lt;li&gt;Popova L.D. (Omsk)&lt;/li&gt;
&lt;li&gt;Portnyagina U.S. (Yakutsk)&lt;/li&gt;
&lt;li&gt;Shamaeva S.Kh. (Yakutsk)&lt;/li&gt;
&lt;li&gt;Shipitsyna E.V. (St. Petersburg)&lt;/li&gt;
&lt;li&gt;Shirokova T.M. (Kirov)&lt;/li&gt;
&lt;li&gt;Sidorova R.K. (Ulyanovsk)&lt;/li&gt;
&lt;li&gt;Strebkova V.V. (Voronezh)&lt;/li&gt;
&lt;li&gt;Sukhoreva M.V. (Irkutsk)&lt;/li&gt;
&lt;li&gt;Tapalsky D.V. (Gomel, Belarus)&lt;/li&gt;
&lt;li&gt;Valiullina I.R. (Kazan)&lt;/li&gt;
&lt;li&gt;Varganova A.N. (Surgut)&lt;/li&gt;
&lt;li&gt;Varibrus E.V. (Krasnodar)&lt;/li&gt;
&lt;li&gt;Vasilyeva I.R. (Nizhnevartovsk)&lt;/li&gt;
&lt;li&gt;Vetokhina A.V. (Irkutsk)&lt;/li&gt;
&lt;li&gt;Volkovskaya I.V. (Tomsk)&lt;/li&gt;
&lt;li&gt;Zhestkov A.V. (Samara)&lt;/li&gt;
&lt;/ul&gt;
&lt;div class=&#34;media&#34;&gt;
  &lt;div class=&#34;media-body&#34;&gt;
    &lt;h3 class=&#34;mt-0 mb-1&#34;&gt;Coordinator&lt;/h3&gt;
    &lt;h5&gt;Ivan S. Palagin&lt;/h5&gt;
    &lt;p&gt;Research fellow&lt;/p&gt;
    &lt;p&gt;Institute of Antimicrobial Chemotherapy (IAC),&lt;br&gt;Smolensk State Medical University (SSMU)&lt;/p&gt;
    &lt;p&gt;&lt;a href=&#34;ivan.palagin@gmail.com&#34; target=&#34;_blank&#34;&gt;ivan.palagin@gmail.com&lt;/a&gt;&lt;/p&gt;
  &lt;/div&gt;
  &lt;img class=&#34;ml-3&#34; src=&#34;iac.png&#34; alt=&#34;Institute of Antimicrobial Chemotherapy&#34;&gt;
&lt;/div&gt;
&lt;h3 id=&#34;publications&#34;&gt;Publications&lt;/h3&gt;
&lt;ol&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, T.S. Perepanova, R.S. Kozlov, “DARMIS-2018” Study Group. Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia, Belarus and Kazakhstan: results of the international multicenter study “DARMIS-2018”. Urology 2020; 1: 19-31.&lt;br/&gt;
&lt;a href=&#34;https://dx.doi.org/10.18565/urology.2020.1.19-31&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;ai ai-doi&#34;&gt;&lt;/i&gt; 10.18565/urology.2020.1.19-31&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, T.S. Perepanova, R.S. Kozlov, “DARMIS-2018” Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. KMAKH 2019; 21 (2): 134-46.&lt;br/&gt;
&lt;a href=&#34;https://doi.org/10.36488/cmac.2019.2.134-146&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;ai ai-doi&#34;&gt;&lt;/i&gt; 10.36488/cmac.2019.2.134-146&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, A.V. Grinev, T.S. Perepanova, R.S. Kozlov, DARMIS Study Group. Complicated community-acquired urinary tract infections in adult patients in Russia. KMAKH 2014; 16 (1): 39-56. &lt;br/&gt;
&lt;a href=&#34;https://cmac-journal.ru/en/publication/2014/1/cmac-2014-t16-n1-p039/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;fas fa-book-open&#34;&gt;&lt;/i&gt; cmac-journal.ru&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;I.S. Palagin, M.V. Sukhorukova, A.V. Dekhnich, M.V. Edelstein, A.N. Shevelev, A.V. Grinev, T.S. Perepanova, R.S. Kozlov, “DARMIS” Study Group. Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia: DARMIS Study (2010-2011). KMAKH 2012; 14 (4): 280-302.&lt;br/&gt;
&lt;a href=&#34;https://cmac-journal.ru/en/publication/2012/4/cmac-2012-t14-n4-p280/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;fas fa-book-open&#34;&gt;&lt;/i&gt; cmac-journal.ru&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;T.S. Perepanova, R.S. Kozlov, A.V. Dekhnich, I.S. Palagin, A.N. Shevelev, E.M. Volkova, D.K. Egamberdiev. Choice of antimicrobial drugs in urinary infections. Urology 2012; 2: 4-8.&lt;br/&gt;
&lt;a href=&#34;https://cyberleninka.ru/article/n/empiricheskiy-vybor-antimikrobnyh-preparatov-pri-neoslozhnennoy-infektsii-nizhnih-mochevyh-putey-issledovanie-rezistentnosti&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;i class=&#34;fas fa-book-open&#34;&gt;&lt;/i&gt; cyberleninka.ru&lt;/a&gt;&lt;/li&gt;
&lt;/ol&gt;
</description>
    </item>
    
    <item>
      <title>&lt;em&gt;Acinetobacter baumannii&lt;/em&gt; genetic diversity, susceptibility to antibiotics and lytic phages</title>
      <link>https://amrcloud.net/en/project/abphage/</link>
      <pubDate>Mon, 10 Feb 2020 00:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/abphage/</guid>
      <description>&lt;h3 id=&#34;abstract&#34;&gt;Abstract&lt;/h3&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Acinetobacter baumannii&lt;/strong&gt;&lt;/em&gt; is one of the most common and troublesome nosocomial pathogens. This project presents the following data on nosocomial &lt;em&gt;A. baumannii&lt;/em&gt; isolates collected from various regions of Russia:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;isolate source data (geographical, clinical data, and basic patient demographics);&lt;/li&gt;
&lt;li&gt;molecular-genetic characteristics of isolates (clonal group, SNP type, sequence type, KL type, presence of acquired carbapenemase genes);&lt;/li&gt;
&lt;li&gt;susceptibility to various antibiotics;&lt;/li&gt;
&lt;li&gt;susceptibility to certain lytic phages.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;bacterial-isolates&#34;&gt;Bacterial isolates&lt;/h3&gt;
&lt;p&gt;The study includes a total of &lt;strong&gt;3,135&lt;/strong&gt; consecutive non-duplicate (one per patient/case of infection) clinical isolates collected between &lt;strong&gt;14 January 2013 and 31 December 2019&lt;/strong&gt; as part of the national surveillance studies from &lt;strong&gt;71 hospitals in 36 cities of Russia&lt;/strong&gt;: : Arkhangelsk, Barnaul, Belgorod, Blagoveshchensk, Chelyabinsk, Irkutsk, Izhevsk, Kazan, Krasnodar, Kurgan, Maykop, Moscow, Murmansk, Naberezhnye Chelny, Nizhny Novgorod, Novosibirsk, Noyabrsk, Omsk, Penza, Perm, Petrozavodsk, Rostov-on-Don, Seversk, Smolensk, St. Petersburg, Tolyatti, Tomsk, Tula, Tver, Tyumen, Ulan-Ude, Vladivostok, Voronezh, Yakutsk, Yekaterinburg, and Yuzhno-Sakhalinsk.&lt;/p&gt;
&lt;h3 id=&#34;antibiotic-susceptibility-testing-ast&#34;&gt;Antibiotic susceptibility testing (AST)&lt;/h3&gt;
&lt;p&gt;Minimum inhibitory concentrations (MICs) of antibiotics were determined by reference broth microdilution method according to ISO 20776-1:2006. The susceptibility categories were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC Clinical Breakpoints v.10.0, 2020 (&lt;a href=&#34;http://www.eucast.org/clinical_breakpoints/&#34;&gt;http://www.eucast.org/clinical_breakpoints/&lt;/a&gt;)&lt;/p&gt;
&lt;h3 id=&#34;phage-susceptibility-testing-pst&#34;&gt;Phage susceptibility testing (PST)&lt;/h3&gt;
&lt;p&gt;Susceptibilities of isolates to selected lytic phages were determined by a modified double-agar-layer method and by spot testing.&lt;/p&gt;
&lt;!-- The results are interpreted as follows: **S** – lysis by phage; **I** – partial lysis; **R** – resistance to phage. PST results are presented together with AST results. --&gt;
&lt;h3 id=&#34;molecular-genetic-subtyping&#34;&gt;Molecular-genetic subtyping&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;All isolates were typed by a single nucleotide polymorphism (SNP)-typing assay based on high-throughput real-time PCR detection of 21informative SNPs in 10 chromosomal loci: &lt;em&gt;gltA, recA, cpn60, gyrB, gdhB, rpoD, fusA, pyrG, rplB,&lt;/em&gt; and &lt;em&gt;rpoB&lt;/em&gt; (&lt;a href=&#34;http://snpt.antibiotic.ru&#34;&gt;http://snpt.antibiotic.ru&lt;/a&gt;:9002/).&lt;/li&gt;
&lt;li&gt;Selected isolates were typed by both the Oxford and Pasteur multilocus sequence typing (MLST) schemes using Sanger or whole genome sequencing (&lt;a href=&#34;https://pubmlst.org/abaumannii/)&#34;&gt;https://pubmlst.org/abaumannii/)&lt;/a&gt;.&lt;/li&gt;
&lt;/ul&gt;
&lt;h3 id=&#34;identification-of-capsular-polysaccharide-biosynthesis-gene-clusters-k-loci-kl&#34;&gt;Identification of capsular polysaccharide biosynthesis gene clusters (K-loci, KL)&lt;/h3&gt;
&lt;p&gt;KL types were identified for selected isolates from WGS data using the standard database and nomenclature (&lt;a href=&#34;https://github.com/katholt/Kaptive)&#34;&gt;https://github.com/katholt/Kaptive)&lt;/a&gt;.&lt;/p&gt;
&lt;h3 id=&#34;detection-of-acquired-carbapenemase-genes&#34;&gt;Detection of acquired carbapenemase genes&lt;/h3&gt;
&lt;p&gt;The genes of the most prevalent in &lt;em&gt;Acinetobacter&lt;/em&gt; spp. acquired carbapenemases of molecular class D (OXA-23-, OXA-24/40- and OXA-58-like), class А (GES-2- or GES-5-like), and class B (VIM, IMP and NDM) were determined by means of real-time PCR.&lt;/p&gt;
&lt;h3 id=&#34;study-group&#34;&gt;Study group&lt;/h3&gt;
&lt;p&gt;Roman S. Kozlov, Anastasia V. Popova, Mikhail M. Shneider, Eugene A. Sheck, Mikhail V. Edelstein, Alexey Yu. Kuzmenkov, Andrey V. Romanov, Elvira R. Shaidullina.&lt;/p&gt;
&lt;h3 id=&#34;funding&#34;&gt;Funding&lt;/h3&gt;
&lt;p&gt;This work was conducted with the financial support of the Russian Science Foundation (grant no. 18-15-00403).&lt;/p&gt;
&lt;hr/&gt;
&lt;div class=&#34;media&#34;&gt;
  &lt;div class=&#34;media-body&#34;&gt;
    &lt;h3 class=&#34;mt-0 mb-1&#34;&gt;Contact&lt;/h3&gt;
    &lt;h5&gt;Evgenii Shek&lt;/h5&gt;
    &lt;p&gt;Research fellow&lt;/p&gt;
    &lt;p&gt;Institute of Antimicrobial Chemotherapy (IAC),&lt;br&gt;Smolensk State Medical University (SSMU)&lt;/p&gt;
    &lt;p&gt;&lt;a href=&#34;evgeniy.sheck@antibiotic.ru&#34; target=&#34;_blank&#34;&gt;evgeniy.sheck@antibiotic.ru&lt;/a&gt;&lt;/p&gt;
  &lt;/div&gt;
  &lt;img class=&#34;ml-3&#34; src=&#34;iac.png&#34; style=&#34;width: 200px&#34; alt=&#34;Institute of Antimicrobial Chemotherapy (IAC), Smolensk State Medical University (SSMU)&#34;&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>Research project: Veterinary monitoring and Risk Analysis of Zoonotic Bacteria Antimicrobial Resistance.</title>
      <link>https://amrcloud.net/en/project/vgnki/</link>
      <pubDate>Fri, 08 Nov 2019 00:00:00 +0000</pubDate>
      <guid>https://amrcloud.net/en/project/vgnki/</guid>
      <description>&lt;h3 id=&#34;russian-state-center-for-quality-and-standardization-of-veterinary-drugs-and-feed&#34;&gt;Russian State Center for Quality and Standardization of Veterinary Drugs and Feed&lt;/h3&gt;
&lt;p&gt;Research Institute of the Federal Service for Veterinary and Phytosanitary Surveillance (ROSSELKHOZNADZOR).&lt;/p&gt;
&lt;p&gt;OIE collaborating Center on Food Safety, Diagnosis and Control of Animal Diseases in Eastern Europe, Central Asia and Transcaucasia.&lt;/p&gt;
&lt;p&gt;Main activities of VGNKI are ensuring veterinary drugs quality, food of animal origin and feed safety, certification and registration of veterinary drugs, feed and feed additives, including GMO-containing.&lt;/p&gt;
&lt;h3 id=&#34;abstract&#34;&gt;Abstract:&lt;/h3&gt;
&lt;p&gt;We present the data on antimicrobial resistance of animal zoonotic bacteria isolates from different regions of Russia to over than 50 antimicrobials from 12 different groups.&lt;/p&gt;
&lt;h4 id=&#34;object&#34;&gt;Object:&lt;/h4&gt;
&lt;p&gt;Isolates of E.coli, Campylobacter spp., Salmonella spp., Enterococcus spp. taken from biomaterial of farm animals (poultry, cattle, reindeer, swine), food and feed materials.&lt;/p&gt;
&lt;h4 id=&#34;method-of-ast&#34;&gt;Method of AST:&lt;/h4&gt;
&lt;p&gt;Broth microdilution (standard EUCAST/ISO/CLSI protocol), Sensititre veterinary custom plates.&lt;/p&gt;
&lt;h4 id=&#34;breakpoints&#34;&gt;Breakpoints:&lt;/h4&gt;
&lt;p&gt;Microbiological end-points – EUCAST ECOFFs (&lt;a href=&#34;https://mic.eucast.org/Eucast2/,&#34;&gt;https://mic.eucast.org/Eucast2/,&lt;/a&gt; ver. 5.26), EUCAST Clinical Breakpoints (ver. 2019), CLSI Clinical Breakpoints (Standards M100S28, VET01S 3rd ed.)&lt;/p&gt;
&lt;h4 id=&#34;methods-of-gene-analysis&#34;&gt;Methods of gene analysis:&lt;/h4&gt;
&lt;p&gt;Whole-genome sequencing (Illumina Miseq).&lt;/p&gt;
&lt;h4 id=&#34;data&#34;&gt;Data:&lt;/h4&gt;
&lt;ul&gt;
&lt;li&gt;Bogomazova A.N.&lt;/li&gt;
&lt;li&gt;Gergel M.A.&lt;/li&gt;
&lt;li&gt;Gordeeva V.D.&lt;/li&gt;
&lt;li&gt;Gritsyuk V.A.&lt;/li&gt;
&lt;li&gt;Ivanova O.E.&lt;/li&gt;
&lt;li&gt;Karabanov S.Yu.&lt;/li&gt;
&lt;li&gt;Komarov A.A.&lt;/li&gt;
&lt;li&gt;Krylova E.V.&lt;/li&gt;
&lt;li&gt;Kulikosky A.V.&lt;/li&gt;
&lt;li&gt;Lenev S.V.&lt;/li&gt;
&lt;li&gt;Lobova P.A.&lt;/li&gt;
&lt;li&gt;Makarov D.A.&lt;/li&gt;
&lt;li&gt;Pleskacheva M.A.&lt;/li&gt;
&lt;li&gt;Pobolelova Yu. I.&lt;/li&gt;
&lt;li&gt;Pomazkova A.V.&lt;/li&gt;
&lt;li&gt;Prasolova O.V.&lt;/li&gt;
&lt;li&gt;Rusakov S.V.&lt;/li&gt;
&lt;li&gt;Soltynskaya I.V.&lt;/li&gt;
&lt;li&gt;Sukhoedova A.V.&lt;/li&gt;
&lt;li&gt;Yatsentuk S.P.&lt;/li&gt;
&lt;/ul&gt;
&lt;blockquote&gt;
&lt;p&gt;You can leave you questions and comments by e-mail: 
&lt;a href=&#34;mailto:phorez@yandex.ru&#34;&gt;phorez@yandex.ru&lt;/a&gt; (Makarov D.A.)&lt;/p&gt;
&lt;/blockquote&gt;
</description>
    </item>
    
  </channel>
</rss>
